• +1-646-491-9876
    • +91-20-67278686

    Search

    Brain Hemorrhage - Pipeline Review, H2 2016

    Brain Hemorrhage - Pipeline Review, H2 2016

    • Report Code ID: RW0001499734
    • Category Pharmaceuticals
    • No. of Pages 49
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Brain Hemorrhage - Pipeline Review, H2 2016

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides an overview of the Brain Hemorrhage (Central Nervous System) pipeline landscape.

    Brain hemorrhage is a type of stroke. It is caused by the bursting of an artery in the brain that leads to localized bleeding in the surrounding tissues. This bleeding kills the brain cells. The common risk factors of brain haemorrhages include head trauma, high blood pressure, aneurysm, blood vessel abnormalities, amyloid angiopathy, blood or bleeding disorders such as hemophilia and sickle cell anemia, liver disease and brain tumors. Symptoms include sudden severe headache, seizures, weakness in an arm or leg, nausea or vomiting, lethargy, changes in vision, tingling or numbness, difficulty in speaking or understanding speech, difficulty in swallowing, difficulty in writing or reading, loss of fine motor skills such as hand tremors, loss of coordination, loss of balance, abnormal sense of taste and loss of consciousness.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Hemorrhage (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Brain Hemorrhage (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively.Brain Hemorrhage.

    Brain Hemorrhage (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Hemorrhage (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Brain Hemorrhage (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Brain Hemorrhage (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Brain Hemorrhage (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Brain Hemorrhage (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Brain Hemorrhage (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Brain Hemorrhage (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents

    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Brain Hemorrhage Overview 6
    Therapeutics Development 7
    Pipeline Products for Brain Hemorrhage - Overview 7
    Brain Hemorrhage - Therapeutics under Development by Companies 8
    Brain Hemorrhage - Pipeline Products Glance 9
    Late Stage Products 9
    Clinical Stage Products 10
    Early Stage Products 11
    Brain Hemorrhage - Products under Development by Companies 12
    Brain Hemorrhage - Companies Involved in Therapeutics Development 13
    Bio Products Laboratory Ltd 13
    Edge Therapeutics Inc 14
    F. Hoffmann-La Roche Ltd 15
    Fina Biotech 16
    MediPost Co Ltd 17
    Pfizer Inc 18
    Remedy Pharmaceuticals Inc 19
    Brain Hemorrhage - Therapeutics Assessment 20
    Assessment by Monotherapy Products 20
    Assessment by Target 21
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Drug Profiles 29
    alteplase - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    aprotinin SR - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    CN-105 - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    glyburide - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    haptoglobin (human) - Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    PF-05230907 - Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    Pneumostem - Drug Profile 38
    Product Description 38
    Mechanism Of Action 38
    R&D Progress 38
    PRC-14 - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    Recombinant Protein to Inhibit tPA and uPA for Intracranial Hemorrhage - Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    RMP-HPE - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    Stem Cell Therapy for Brain Stroke - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    Brain Hemorrhage - Dormant Projects 45
    Brain Hemorrhage - Discontinued Products 46
    Brain Hemorrhage - Product Development Milestones 47
    Featured News & Press Releases 47
    Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage 47
    Appendix 48
    Methodology 48
    Coverage 48
    Secondary Research 48
    Primary Research 48
    Expert Panel Validation 48
    Contact Us 48
    Disclaimer 49

    List of Tables

    Number of Products under Development for Brain Hemorrhage, H2 2016 7
    Number of Products under Development by Companies, H2 2016 8
    Comparative Analysis by Late Stage Development, H2 2016 9
    Comparative Analysis by Clinical Stage Development, H2 2016 10
    Comparative Analysis by Early Stage Development, H2 2016 11
    Products under Development by Companies, H2 2016 12
    Brain Hemorrhage - Pipeline by Bio Products Laboratory Ltd, H2 2016 13
    Brain Hemorrhage - Pipeline by Edge Therapeutics Inc, H2 2016 14
    Brain Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 15
    Brain Hemorrhage - Pipeline by Fina Biotech, H2 2016 16
    Brain Hemorrhage - Pipeline by MediPost Co Ltd, H2 2016 17
    Brain Hemorrhage - Pipeline by Pfizer Inc, H2 2016 18
    Brain Hemorrhage - Pipeline by Remedy Pharmaceuticals Inc, H2 2016 19
    Assessment by Monotherapy Products, H2 2016 20
    Number of Products by Stage and Target, H2 2016 22
    Number of Products by Stage and Mechanism of Action, H2 2016 24
    Number of Products by Stage and Route of Administration, H2 2016 26
    Number of Products by Stage and Molecule Type, H2 2016 28
    Brain Hemorrhage - Dormant Projects, H2 2016 45
    Brain Hemorrhage - Discontinued Products, H2 2016 46

    List of Figures

    Number of Products under Development for Brain Hemorrhage, H2 2016 7
    Number of Products under Development by Companies, H2 2016 8
    Comparative Analysis by Early Stage Products, H2 2016 11
    Assessment by Monotherapy Products, H2 2016 20
    Number of Products by Targets, H2 2016 21
    Number of Products by Stage and Targets, H2 2016 21
    Number of Products by Mechanism of Actions, H2 2016 23
    Number of Products by Stage and Mechanism of Actions, H2 2016 23
    Number of Products by Routes of Administration, H2 2016 25
    Number of Products by Stage and Routes of Administration, H2 2016 25
    Number of Products by Molecule Types, H2 2016 27
    Number of Products by Stage and Molecule Types, H2 2016 27
    Bio Products Laboratory Ltd
    Edge Therapeutics Inc
    F. Hoffmann-La Roche Ltd
    Fina Biotech
    MediPost Co Ltd
    Pfizer Inc
    Remedy Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//brain-hemorrhage-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//brain-hemorrhage-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//brain-hemorrhage-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments